Silvia Ribback

List of Publications by Year
in descending order

42 papers	1,723 citations	304743 22 h-index	289244 40 g-index
46 all docs	46 docs citations	46 times ranked	2663 citing authors

#	Article	IF	Citations
1	TAZ is indispensable for c-MYC-induced hepatocarcinogenesis. Journal of Hepatology, 2022, 76, 123-134.	3.7	28
2	CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype. Journal of Experimental and Clinical Cancer Research, 2022, 41, 65.	8.6	7
3	Î²-Catenin Sustains and Is Required for YES-associated Protein Oncogenic Activity in Cholangiocarcinoma. Gastroenterology, 2022, 163, 481-494.	1.3	13
4	The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease. Journal of Experimental and Clinical Cancer Research, 2022, 41, .	8.6	10
5	Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 1095-1117.	4.5	21
6	Fascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development. Communications Biology, 2021, 4, 763.	4.4	6
7	Overexpression of Mothers Against Decapentaplegic Homolog 7 Activates the Yesâ€Associated Protein/NOTCH Cascade and Promotes Liver Carcinogenesis in Mice and Humans. Hepatology, 2021, 74, 248-263.	7.3	22
8	YAP Accelerates Notch-Driven Cholangiocarcinogenesis via mTORC1 in Mice. American Journal of Pathology, 2021, 191, 1651-1667.	3.8	12
9	Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. Journal of Hepatology, 2021, 75, 888-899.	3.7	45
10	Hormonally Induced Hepatocellular Carcinoma in Diabetic Wild Type and Carbohydrate Responsive Element Binding Protein Knockout Mice. Cells, 2021, 10, 2787.	4.1	1
11	Tetraspanin 5 (TSPAN5), a Novel Gatekeeper of the Tumor Suppressor DLC1 and Myocardin-Related Transcription Factors (MRTFs), Controls HCC Growth and Senescence. Cancers, 2021, 13, 5373.	3.7	6
12	Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis. International Journal of Molecular Sciences, 2020, 21, 8467.	4.1	20
13	Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis. Cell Death and Differentiation, 2020, 27, 2330-2343.	11.2	39
14	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2019, 25, 403-413.	7.0	56
15	SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelialâ€"Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Research, 2019, 79, 5563-5574.	0.9	12
16	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by Î²-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6.	16.2	92
17	Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. Journal of Hepatology, 2019, 71, 742-752.	3.7	44
18	The mTORC2â€Akt1 Cascade Is Crucial for câ€Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology, 2019, 70, 1600-1613.	7.3	70

#	Article	IF	Citations
19	Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer, 2019, 19, 343.	2.6	17
20	TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. American Journal of Pathology, 2019, 189, 1077-1090.	3.8	25
21	A novel preclinical model of cholangiocarcinoma based on human aberrant FBXW7 expression.. Journal of Clinical Oncology, 2019, 37, e15624-e15624.	1.6	0
22	Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans. American Journal of Pathology, 2018, 188, 995-1006.	3.8	29
23	Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death and Disease, 2018, 9, 31.	6.3	23
24	Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway. Experimental and Molecular Medicine, 2018, 50, e417-e417.	7.7	39
25	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU International, 2018, 121, 84-92.	2.5	22
26	Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle, 2018, 17, 1496-1512.	2.6	14
27	Both <i>de novo</i> synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells. Liver International, 2017, 37, 80-89.	3.9	60
28	Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma. Cell Cycle, 2017, 16, 499-507.	2.6	45
29	A functional mammalian target of rapamycin complex 1 signaling is indispensable for câ€Mycâ€driven hepatocarcinogenesis. Hepatology, 2017, 66, 167-181.	7.3	119
30	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology, 2017, 67, 1194-1203.	3.7	77
31	Clear cell hepatocellular carcinoma: origin, metabolic traits and fate of glycogenotic clear and ground glass cells. Hepatobiliary and Pancreatic Diseases International, 2017, 16, 570-594.	1.3	21
32	Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development. Oncotarget, 2017, 8, 73433-73447.	1.8	26
33	Hepatocellular glycogenotic foci after combined intraportal pancreatic islet transplantation and knockout of the carbohydrate responsive element binding protein in diabetic mice. Oncotarget, 2017, 8, 104315-104329.	1.8	7
34	Activated mutant forms of <scp>PIK</scp>3<scp>CA</scp> cooperate with RasV12 or câ€Met to induce liver tumour formation in mice via <scp>AKT</scp>2/<scp>mTORC</scp>1 cascade. Liver International, 2016, 36, 1176-1186.	3.9	26
35	Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice. Scientific Reports, 2016, 6, 20484.	3.3	100
36	Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans. Hepatology, 2016, 63, 1900-1913.	7.3	82

#	Article	IF	Citations
37	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. Journal of Hepatology, 2016, 64, 333-341.	3.7	115
38	PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men. Oncotarget, 2015, 6, 13036-13048.	1.8	42
39	Activation of Î²-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice. Gastroenterology, 2014, 147, 690-701.	1.3	249
40	Molecular and metabolic changes in human liver clear cell foci resemble the alterations occurring in rat hepatocarcinogenesis. Journal of Hepatology, 2013, 58, 1147-1156.	3.7	26
41	V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis. Hepatology, 2012, 55, 1473-1484.	7.3	50
42	Nodular hemangiomatosis of pleura and peritoneum. Pathology Research and Practice, 2011, 207, 718-721.	2.3	3